prostate cancer
Conditions
Interventions
single arm:abiraterone
Sponsors
Renji Hospital, Shanghai Jiaotong University of Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) According to the EAU-ESTRO-SIOG 2016 guidelines, the clinical diagnosis is mCRPC; 2) Patients with poor prognosis mCRPC, defined as (2019ASCO abs5003): liver metastasis, or progression to CRPC within 12 months of ADT treatment, or >= 4 in the following prognostic features (LDH>ULN; ECOG PS 2; visceral metastasis) ; AlbuminULN; starting at ADT = 3000/mm3 or absolute neutrophil count >= 1500/mm3, AST and ALT are lower than 1.5 ULN; 9) When signing the informed consent form, the age is equal to or greater than 18 years old and less than 75 years old; 10) The investigator expects the patient to survive for more than 3 months; 11) Patients agree and have the ability to follow planned study visits, provide blood samples before and after treatment, provide clinical information and coordinate with other research steps.
Exclusion criteria
Exclusion criteria: 1) The investigator judges that the patient has other serious diseases that may affect follow-up and short-term survival, and any medical reasons show a significant risk of death during the 1-year study period; 2) Previous diagnosis of any other malignant tumor; 3) There are other malignant tumors at the same time; 4) The clinical information required for the study cannot be obtained (eg, the patient is lost); 5) Other investigators believe that it is not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;PSA response;quality of life; | — |
Countries
China
Contacts
Public ContactWei Xue
Renji Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed